The role of adrenergic receptor polymorphisms in heart failure

Brazilian Journal of Medical and Biological Research

Volumn 39, Issue 10, 2006, Pages 1281-1290

  Biolo, A ^a   Rosa, A S ^a   Mazzotti, N G ^a   Martins, S ^a   Bello Klein A ^b   Rohde, L E ^a   Clausell, N ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Adrenergic receptor; Heart failure; Polymorphisms

Indexed keywords

ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; MOXONIDINE; NORADRENALIN;

ADRENERGIC SYSTEM; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE COURSE; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HEART FAILURE; HEART OUTPUT; HEART WORK; HUMAN; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 33847707816     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006001000003     Document Type: Review

References (48)

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.
2. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol 1997; 80: 7L-14L.
3. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999; 353: 9-13.
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
5. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289: 712-718.
6. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 2001; 33: 887-905.
7. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990; 82: I-12-I-25.
8. Hajjar RJ, MacRae CA. Adrenergic receptor polymorphisms and heart failure. N Engl J Med 2002; 347: 1196-1199.
9. Brodde OE, Bruck H, Leineweber K, Seyfarth T. Presence, distribution and physiological function of adrenergic and muscarinic receptor subtypes in the human heart. Basic Res Cardiol 2001; 96: 528-538.
10. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999; 402: 181-184.
11. Brodde OE. The functional importance of beta 1 and beta 2 adrenoceptors in the human heart. Am J Cardiol 1988; 62: 24C-29C.
12. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59: 297-309.
13. Bristow MR, Port JD, Kelly RA. Treatment of heat failure: pharmacological methods. In: Braunwald E, Zipes DP, Libby P (Editors), Heart disease: a textbook of cardiovascular medicine. 6th edn. Orlando: W.B. Saunders; 2001. p 562-599.
14. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A, et al. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998; 102: 1377-1384.
15. Chakraborti S, Chakraborti T, Shaw G. Beta-adrenergic mechanisms in cardiac diseases: a perspective. Cell Signal 2000; 12: 499-513.
16. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999; 100: 2210-2212.
17. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998; 98: 1329-1334.
18. Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 2003; 177: 391-398.
19. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
20. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
21. Rodefeld MD, Beau SL, Schuessler RB, Boineau JP, Saffitz JE. Beta-adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: identification of a high beta 2-adrenergic receptor density. J Cardiovasc Electrophysiol 1996; 7: 1039-1049.
22. Dzimiri N. Regulation of beta-adrenoceptor signaling in cardiac function and disease. Pharmacol Rev 1999; 51: 465-501.
23. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993; 22: 61A-71A.
24. Ahmed A. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. Eur J Heart Fail 2003; 5: 709-715.
25. Hadcock JR, Malbon CC. Down-regulation of beta-adrenergic receptors: agonist-induced reduction in receptor mRNA levels. Proc Natl Acad Sci USA 1988; 85: 5021-5025.
26. Bristow MR, Minobe WA, Reynolds MV, Port JD, Rasmussen R, Ray PE, et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993; 92: 2737-2745.
27. Liang W, Austin S, Hoang Q, Fishman PH. Resistance of the human beta 1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining beta-subtype degradation. J Biol Chem 2003; 278: 39773-39781.
28. Kimball JW. Kimball's Biology Pages. http://home.comcast.net/ john.kimball1/BiologyPages/. Accessed December 12, 2004.
29. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 1996; 93: 10483-10488.
30. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998; 102: 1927-1932.
31. Levin MC, Marullo S, Muntaner O, Andersson B, Magnusson Y. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002; 277: 30429-30435.
32. Rathz DA, Brown KM, Kramer LA, Liggett SB. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002; 39: 155-160.
33. Borjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21: 1853-1858.
34. Podlowski S, Wenzel K, Luther HP, Muller J, Bramlage P, Baumann G, et al. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 2000; 78: 87-93.
35. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274: 12670-12674.
36. White HL, De Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003; 5: 463-468.
37. Mialet PJ, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9: 1300-1305.
38. Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347: 1135-1142.
39. Tesson F, Charron P, Peuchmaurd M, Nicaud V, Cambien F, Tiret L, et al. Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. J Mol Cell Cardiol 1999; 31: 1025-1032.
40. Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, Dorn GW, et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 2002; 144: 840-846.
41. Iwai C, Akita H, Shiga N, Takai E, Miyamoto Y, Shimizu M, et al. Suppressive effect of the Gly389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 2002; 66: 723-728.
42. Liggett SB, Wagoner LE, Craft LL, Homung RW, Hoit BD, McIntosh TC, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-1539.
43. Parker JD, Newton GE, Landzberg JS, Floras JS, Colucci WS. Functional significance of presynaptic alpha-adrenergic receptors in failing and nonfailing human left ventricle. Circulation 1995; 92: 1793-1800.
44. Small KM, Forbes SL, Rahman FF, Bridges KM, Liggett SB. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000; 275: 23059-23064.
45. Sabbah HN. Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev 2004; 9: 91-97.
46. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation 2003; 107: 1100-1102.
47. Coats AJ. Heart Failure 99 - the MOXCON story. Int J Cardiol 1999; 71: 109-111.
48. Beta-blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.